Immune Pharmaceuticals Inc

Immune Pharmaceuticals — Investor Presentation (February 2016)

43 slides from Immune Pharmaceuticals's investor presentation, Feb 8, 2016

  1. Slide 1: February 2016 Investor Presentation

    February 2016 Investor Presentation Dr. Daniel Teper , CEO

  2. Slide 2: Forward Looking Statement

    Forward Looking Statement This presentation and any oral statements made with respect to the information contained in this presentation contain forward - looking statements that involve risks and uncertainties regarding the operations and future results of Immune Pharmaceuticals , Inc. You are urged

  3. Slide 3: Agenda

    Agenda • Corporate Overview • Immuno - Inflammation • Immuno - Oncology • Immune Pharmaceuticals Valuation Drivers

  4. Slide 4: 2016 Investor Highlights: Unlocking the Value of IMNP Pipeline

    2016 INVESTOR HIGHLIGHTS: Unlocking the Value of IMNP Pipeline • NASDAQ - listed company focused on Immuno - Inflammation and Immuno - Oncology • Unlocking the Value of Bertilimumab – Lead Phase II Asset, Bertilimumab, targets Dermatology (Bullous Pemphigoid - BP , Atopic dermatitis - AD) and GI (Cr

  5. Slide 5: A Broad Immuno-Inflammation and Immuno-Oncology Pipeline – Focus on Bertilimumab

    A Broad Immuno - Inflammation and Immuno - Oncology Pipeline – Focus on Bertilimumab P2 Clinical Preclinical Phase I Phase II Phase III Registration Bertilimumab UC Bullous Pemphigoid Atopic Dermatitis Topical Nano - Cyclosporine Psoriasis and AD Ceplene Approved in EU Post - marketing data in 2016

  6. Slide 6: R&D Centers & Capabilities

    R & D Centers & Capabilities Alexandria Center for Life Science, NYC Company HQs Immunology R&D lab Translational R&D Jerusalem, IL Hadassah/Hebrew U Bio Park Campus Nanotechnology R&D Translational R&D

  7. Slide 7: New Leadership Team Focused on Execution

    New Leadership Team Focused on Execution Daniel Teper , PharmD , MBA Founder & CEO Novartis , GSK, Sanofi , Bionest Monica Luchi, MD EVP , Chief Medical Officer Mesoblast , Incyte , Novartis John Mohr, CPA SVP , Business Development Merck & Co, CV Therapeutics, Fournier Pharma USA Miri Ben - Ami , M

  8. Slide 8: New Leadership Team's Combined Experience

    New Leadership Team’s Combined Experience

  9. Slide 9: 2015 Key Events

    2015 Key Events • Relocated Company Headquarters to Alexandria Center in NYC • Expanded leadership team in all key functional areas • Raised capital to support clinical development to phase 2 data for bertilimumab • First patient and on - going enrollment in Phase 2 bertilimumab trials • Received FD

  10. Slide 10: 2016 Expected Events

    2016 Expected Events • Clinical results for bertilimumab Phase 2 study in BP • Clinical results for bertilimumab Phase 2 study in UC • Pre - clinical data and initiation of phase 2 for bertilimumab in Atopic Dermatitis • IND submission for topical nano - cyclosporin • Commercialization partner for C

  11. Slide 11: Immuno-Inflammation: Improving the lives of patients with chronic inflammatory diseases

    Immuno - Inflammation: Improving the lives of patients with chronic inflammatory diseases

  12. Slide 12: Immuno-Inflammation Pipeline

    Discovery Preclinical Phase I Phase II Phase III Registration Bertilimumab Ulcerative Colitis (UC) Bullous Pemphigoid (BP) Atopic Dermatitis (AD) Topical Nano - Cyclosporine Psoriasis and AD IMMUNO - INFLAMMATION PIPELINE Bertilimumab: “A Portfolio in a Drug”

  13. Slide 13: Bertilimumab: First-in-Class Fully Human Monoclonal Antibody Targeting Eotaxin-1

    First - in - Class Fully Human Monoclonal Antibody Targeting and Neutralizing Eotaxin - 1 , A Key Regulator of Immuno - Inflammation BERTILIMUMAB

  14. Slide 14: Eotaxin-1: A Key Regulator of Immuno-Inflammation

    EOTAXIN - 1 - REGULATED CELL MIGRATION AND ACTIVATION CELLS SECRETING EOTAXIN - 1 EOTAXIN - 1 : A Key Regulator Of Immuno - Inflammation Modulates cross talk between key cells involved in immune response through CCR 3 receptor EOTAXIN - 1 Key Regulator in: Gastro Intestinal Liver Lungs Skin Eosinoph

  15. Slide 15: Bertilimumab Safe with Dose-Dependent Biological Activity in Phase I

    BERTILIMUMAB was Safe and Showed Dose – Dependent, Rapid Onset and Lasting Biological Activity In Phase I Clinical Trials

  16. Slide 16: Bertilimumab: A Pipeline in a Drug

    BERTILIMUMAB: A PIPELINE IN A DRUG With Initial Focus On Gastro - Enterology And Dermatology • Severe Asthma • COPD • Ulcerative Colitis • Crohn ’ s Disease • Alzheimer ’ s Disease • NASH (Non - Alcoholic Steatohepatitis) • PSC (Primary Sclerosing Cholangitis ) • Atopic Dermatitis • Bullous Pemphigo

  17. Slide 17: Improving the Lives of Patients with Ulcerative Colitis and Crohn's Disease

    Improving the Lives of Patients with Ulcerative Colitis and Crohn’s Disease

  18. Slide 18: Targeting Eotaxin in IBD Patients

    TARGETING EOTAXIN IN IBD PATIENTS Supported by Experimental and Clinical Data Bertilimumab has potential to eliminate Eotaxin - 1 positive feedback loop Waldenmeyer J, Role of Gastrointestinal eosinophils in inflammatory bowel disease and intestinal tumors, Best Pract Res Clin Gastroenterol . 2008 ;

  19. Slide 19: Eotaxin as Therapeutic Target and Biomarker in Ulcerative Colitis

    EOTAXIN – 1 As a Therapeutic Target a nd a Biomarker for Patient Selection in Ulcerative Colitis Coburn LA et al., PLoS One, 2013 ; 8 ( 12 ): e 82300 LIFESCI ADVISORS LIFESCI ADVISORS Equity Research Page 2 January 21, 2014 Only Eotaxin-1 is Increased in Both Serum and Tissue Samples from UC Patient

  20. Slide 20: Bertilimumab Phase II Development in Bullous Pemphigoid and Atopic Dermatitis

    BERTILIMUMAB Phase II Development In Bullous Pemphigoid and Atopic Dermatitis

  21. Slide 21: Eotaxin-1 Correlated with Disease Severity in Bullous Pemphigoid

    Eotaxin - 1 is Correlated with Disease Severity in Bullous Pemphigoid, an Auto - Immune Blistering Skin Disease Levels of Eotaxin - 1 significantly Increased both in sera and blister fluids Eotaxin - 1 up - regulated in serum of BP patients and correlates w/ disease severity* † PV - pemphigus vulgar

  22. Slide 22: Bertilimumab Neutralizes Eotaxin in Bullous Pemphigoid

    BERTILIMUMAB NEUTRALIZES EOTAXIN – 1 , A Key Regulator Of Immuno – Inflammation In Bullous Pemphigoid Source: Dr. Neil Korman , Case Western

  23. Slide 23: Eotaxin Role in Atopic Dermatitis

    EOTAXIN - 1 ROLE IN ATOPIC DERMATITIS (AD) Supports Therapeutic Intervention With Dupilumab o r Bertilimumab Histologic examination of hematoxylin and eosin stained sections from AD NS - normal skin NL - Non lesional LS - lesional skin a - mononuclear cells b - fibroblasts c - eosinophils Eotaxin mR

  24. Slide 24: Two Drugs in Immuno-Dermatology

    Immune is developing two game - changing drugs in Immuno - Dermatology

  25. Slide 25: Topical Nano-Cyclosporine

    Transforming the treatment of Moderate Atopic Dermatitis and Moderate Psoriasis TOPICAL NANO - CYCLOSPORINE

  26. Slide 26: Topical Nano-Cyclosporine: Market Opportunity

    Topical Nano - Cyclosporine ( CyA ) A $ 1 + B Market Opportunity in the Treatment of Moderate Atopic Dermatitis (AD) and Moderate Psoriasis Electron microscopy pictures - Prof.Benita (HUJ) • Game changing topical formulation of gold standard oral CyA • Excellent dermal penetration • Long - term form

  27. Slide 27: Potential Peak Sales for Immuno-Inflammation Franchise

    $ 5 B Potential Peak Sales for Immuno - Inflammation Franchise (Bertilimumab and Nano - Cyclosporine) $ 2 B GASTRO Crohn’s & Colitis $ 2 B DERM AD and BP $ 1 B NANO - CYCLO Nano - Cyclo $ 1 B Bertilimumab Gastro (Crohn’s & Colitis) $ 2 B Bertilimumab Derm (AD & BP) $ 2 B

  28. Slide 28: Immuno-Oncology: Advancing Toward Cure For Patients With Cancer

    IMMUNO - ONCOLOGY Advancing Toward Cure For Patients With Cancer

  29. Slide 29: Immunotherapy – The Beginning of the End for Cancer

    Immunotherapy – The Beginning of the End for Cancer Cancer is a leading cause of death worldwide, accounting for 8.2 million deaths in 2012 . Cancer prevalence is increasing due to growth and aging Economic cost in US alone in 2010 - $ 157 billion Potential Cancer Immunotherapy market opportunity in

  30. Slide 30: Immuno-Oncology Portfolio Across All Stages of Development

    30 IMMUNO - ONCOLOGY PORTFOLIO Across All Stages of Development Discovery Preclinical Phase I Phase II Phase III Registration Ceplene Approved in EU Post - marketing data in 2016 Azixa Crolibulin Bispecific Antibodies NanomAbs

  31. Slide 31: 2016 Immuno-Oncology Milestones

    2016 Immuno - Oncology Milestones CEPLENE : • New data on effect of Ceplene +low dose IL 2 immunotherapy on subpopulations based on biomarker profiling • Partnership for advanced clinical development and commercialization VASCULAR DISRUPTING AGENTS ( A ZIXA AND C ROLIBULIN ): • Pre - clinical confir

  32. Slide 32: Ceplene: Combination Immunotherapy in Acute Myeloid Leukemia

    Combination Immunotherapy for maintenance and prevention of relapse in Acute Myeloid Leukemia CEPLENE

  33. Slide 33: Ceplene/IL-2 Mechanism of Action

    Lysed AML blasts NKp 46 Activating receptors Myeloid leukemic cell NK cell 2 H receptor Cytotoxicity Ceplene O 2 AML blasts NKp 3 0 NADP H oxidas e Response to IL - 2 Apoptosis 2 targets H Ceplene receptor co - expressed with NADPH/NOX 2 oxidase, reducing or inhibiting ROS production X NK Activation

  34. Slide 34: Phase III Ceplene/IL-2 Study Met Primary Endpoint

    Phase 3 Ceplene/IL - 2 Study Met Primary Endpoint % Leukemia - free Survival Overall Population CR 1 Population Ceplene /IL - 2 (n= 160 ) Control (n= 160 ) Ceplene /IL - 2 (n= 129 ) Control (n= 132 ) P = 0.008 P = 0.011 Months from Randomization Months from Randomization

  35. Slide 35: Benefit of Ceplene Immunotherapy by Direct Action on H2R Leukemia Cells

    Significant Benefit of Ceplene based - Immunotherapy by Direct Action of Ceplene on H 2 R Leukemia Cells in P 3 trial 35 Kaplan - Meier plots of LFS for patients in CR 1 (< 60 years old) receiving post consolidation Immunotherapy with Ceplene/IL - 2 or standard - of - care. FAB classification was gr

  36. Slide 36: Ceplene/IL-2: Remission Maintenance Therapy for AML

    Ceplene /IL - 2 : Remission maintenance therapy for patients with AML • Lack of other effective/approved therapies for AML following CR 1 • Excellent safety profile and proven clinical efficacy in pivotal Ph 3 trial • IL - 2 monotherapy is now known to lack clinical efficacy for remission maintenanc

  37. Slide 37: Azixa & Crolibulin: Combination Therapy

    Combination Therapy with Avastin and with Check Point Inhibitors AZIXA & CROLIBULIN

  38. Slide 38: Azixa and Crolibulin Act as Vascular Disrupting Agents

    Azixa and Crolibulin act as Vascular Disrupting Agents (VDAs) • Involves selective targeting of microtubule network in endothelial cells of the tumor neo - vasculature – Characterized by rapid loss of neo - vascular integrity, tumor hemorrhage and necrosis of central tumor tissue vascular disruption

  39. Slide 39: Pre-Clinical and Phase I/II Data Support VDA Combination Development

    Pre - Clinical and Phase I/II Clinical Data support further VDA combination therapy development • 167 patient experience with Azixa • Azixa evades multi - drug resistance (MDR) and penetrates into the brain • Azixa has shown e arly efficacy and long term survival signal in brain tumors ( glioma ) •

  40. Slide 40: Bispecific Antibodies and NanomAbs Platforms

    Two platforms with focus on immune check points and other novel targets - 2 Units with Bivalent binding - Targets two receptors on one cell or two different cells - Tri - functional Abs NanomAbs: Immuno - Nano Particles Polymeric PLGA PEG Coated (Stealth Effect ) Up to 20,000 drugs Up to 50 mAbs con

  41. Slide 41: 2016 Unlocking the Value of IMNP

    2016 Unlocking the Value of IMNP

  42. Slide 42: 2016: Unlocking the Value of IMNP

    2016 : Unlocking the Value of IMNP • Unlocking the Value of Bertilimumab through phase II clinical data • Expanding the Dermatology Franchise with Topical nano - cyclosporin • Unlocking the Value of the Immuno - Oncology pipeline with new data and organization/ funding of a private subsidiary • Unlo

  43. Slide 43: Questions & Answers Thank You

    Questions & Answers Thank You Dr. Daniel Teper CEO daniel.teper@immunepharma.com © Copyright 2016 Immune Pharmaceuticals

Immune Pharmaceuticals — Investor Presentation (February 2016) on 6ix